MX2020013730A - Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario. - Google Patents

Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario.

Info

Publication number
MX2020013730A
MX2020013730A MX2020013730A MX2020013730A MX2020013730A MX 2020013730 A MX2020013730 A MX 2020013730A MX 2020013730 A MX2020013730 A MX 2020013730A MX 2020013730 A MX2020013730 A MX 2020013730A MX 2020013730 A MX2020013730 A MX 2020013730A
Authority
MX
Mexico
Prior art keywords
modulator
immune checkpoint
checkpoint molecule
iap inhibitor
combination
Prior art date
Application number
MX2020013730A
Other languages
English (en)
Inventor
Guangfeng Wang
Qiuqiong Tang
Dajun Yang
Yifan Zhai
Douglas Dong Fang
Wentao Pan
jiao Ji
Original Assignee
Ascentage Pharma Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma Suzhou Co Ltd filed Critical Ascentage Pharma Suzhou Co Ltd
Publication of MX2020013730A publication Critical patent/MX2020013730A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente divulgación pertenece al campo de la biomedicina y se refiere específicamente a un método para tratar, suprimir, reducir la gravedad de, disminuir el riesgo de o inhibir la metástasis del cáncer en un individuo, comprendiendo el método administrar al individuo una cantidad terapéuticamente eficaz de un inhibidor de IAP, una cantidad terapéuticamente eficaz de un modulador de una molécula de punto de control inmunitario y opcionalmente una cantidad terapéuticamente eficaz de un inhibidor de la tubulina. La presente divulgación se refiere además a una composición farmacéutica o kit que comprende un inhibidor de IAP, un modulador de una molécula de punto de control inmunitario y opcionalmente un inhibidor de la tubulina.
MX2020013730A 2018-07-31 2019-07-30 Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario. MX2020013730A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810859866 2018-07-31
CN2019074791 2019-02-11
CN2019088527 2019-05-27
CN201910575352 2019-06-28
PCT/CN2019/098331 WO2020024932A1 (en) 2018-07-31 2019-07-30 Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule

Publications (1)

Publication Number Publication Date
MX2020013730A true MX2020013730A (es) 2021-05-27

Family

ID=69230976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013730A MX2020013730A (es) 2018-07-31 2019-07-30 Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario.

Country Status (11)

Country Link
US (1) US20210330642A1 (es)
EP (1) EP3829639A4 (es)
JP (1) JP2021533124A (es)
KR (1) KR20210073489A (es)
CN (1) CN110898226B (es)
AU (1) AU2019314728A1 (es)
BR (1) BR112021001796A2 (es)
CA (1) CA3101835A1 (es)
MX (1) MX2020013730A (es)
TW (1) TW202012411A (es)
WO (1) WO2020024932A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992755A1 (ru) 2017-05-19 2020-04-22 Уси Байолоджикс (Шанхай) Ко. Лтд. Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
TWI776451B (zh) * 2020-04-10 2022-09-01 大陸商蘇州亞盛藥業有限公司 Bcl-2/bcl-xl抑制劑之組合及相關用途
WO2022179490A1 (en) * 2021-02-23 2022-09-01 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical compositions and preparation methods thereof
WO2023040804A1 (zh) * 2021-09-14 2023-03-23 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法
CN117070203A (zh) * 2023-07-28 2023-11-17 长江大学 一种高温高盐油藏两亲性纳米驱油剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2014031487A1 (en) 2012-08-23 2014-02-27 The Regentis Of The University Of Michigan Bivalent inhibitors of iap proteins and therapeutic methods using the same
CA2974651A1 (en) * 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EA201891904A1 (ru) 2016-02-24 2019-04-30 Чилдрен'С Хоспитал Оф Истерн Онтарио Рисерч Инститьют Инк. Smc комбинированная терапия для лечения злокачественного новообразования
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Also Published As

Publication number Publication date
EP3829639A4 (en) 2022-06-29
BR112021001796A2 (pt) 2021-05-18
EP3829639A1 (en) 2021-06-09
US20210330642A1 (en) 2021-10-28
AU2019314728A1 (en) 2020-12-17
CA3101835A1 (en) 2020-02-06
CN110898226A (zh) 2020-03-24
CN110898226B (zh) 2023-05-05
TW202012411A (zh) 2020-04-01
KR20210073489A (ko) 2021-06-18
WO2020024932A1 (en) 2020-02-06
JP2021533124A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2020013730A (es) Metodo para tratar el cancer mediante la combinacion de un inhibidor de iap y un modulador de una molecula de punto de control inmunitario.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
ZA202007007B (en) Mcl-1 inhibitors
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
EP4279087A3 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MX2020009256A (es) Compuestos para el tratamiento de cancer.
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2019005831A (es) Aptameros para usarse en la inhibicion y/o supresion de la activacion de tlr9.
ZA201901367B (en) Inhibition of olig2 activity
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.